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Hepatitis C virus has been identiﬁed a quarter of a decade ago as a
leading cause of chronic viral hepatitis that can lead to cirrhosis
and hepatocellular carcinoma. Only a minority of patients can
clear the virus spontaneously during acute infection. Elimination
of HCV during acute infection correlates with a rapid induction of
innate, especially interferon (IFN) induced genes, and a delayed
induction of adaptive immune responses. However, the majority
of patients is unable to clear the virus and develops viral persis-
tence in face of an ongoing innate and adaptive immune
response. The virus has developed several strategies to escape
these immune responses. For example, to escape innate
immunity, the HCV NS3/4A protease can efﬁciently cleave and
inactivate two important signalling molecules in the sensory
pathways that react to HCV pathogen-associated molecular pat-
terns (PAMPs) to induce IFNs, i.e., the mitochondrial anti-viral
signalling protein (MAVS) and the Toll-IL-1 receptor-domain-
containing adaptor-inducing IFN-b (TRIF). Despite these escape
mechanisms, IFN-stimulated genes (ISGs) are induced in a large
proportion of patients with chronic infection. Of note, chronically
HCV infected patients with constitutive IFN-stimulated gene
(ISG) expression have a poor response to treatment with pegylat-
ed IFN-a (PegIFN-a) and ribavirin. The mechanisms that protect
HCV from IFN-mediated innate immune reactions are not entirely
understood, but might involve blockade of ISG protein translation
at the ribosome, localization of viral replication to cell compart-
ments that are not accessible to anti-viral IFN-stimulated effector
systems, or direct antagonism of effector systems by viralJournal of Hepatology 20
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achieved by emergence of viral escape mutations that avoid rec-
ognition by antibodies and T cells. In addition, chronic infection is
characterized by the presence of functionally and phenotypically
altered NK and T cell responses that are unable to clear the virus
but most likely contribute to the ongoing liver disease. In this
review, we will summarize current knowledge about the role of
innate and adaptive immune responses in determining the out-
come of HCV infection.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatitis C virus
Hepatitis C virus (HCV) infects 130 to 170 million persons world-
wide [1]. HCV is parenterally transmitted, mainly due to injection
drug use and unsafe transfusions and therapeutic injections [2].
Acute HCV infections (AHC) are often oligo- or asymptomatic
[3]. In 70–80% of those infected, the virus persists and the infec-
tion becomes chronic. Spontaneous clearance of HCV is rare in
the chronic phase of the infection. In most patients, chronic hep-
atitis C (CHC) leads to some degree of liver ﬁbrosis, and in 15–25%
of patients cirrhosis develops after 10 to 40 years [4]. Patients
with CHC and cirrhosis are at increased risk for liver failure and
for developing hepatocellular carcinoma [5].
Innate immunity and interferons
Innate immune responses are the ﬁrst line of defence against
viral infections and interferons (IFNs) are the central cytokines
responsible for the induction of an antiviral state in cells and
for the activation and regulation of the cellular components of
innate immunity, such as natural killer (NK) cells [6]. Type I IFNs
(comprising several IFN-a and one IFN-b) and type III IFNs (IFN-
k1, -k2, and -k3; also designated IL29, IL28A, and IL28B) are pro-
duced by cells infected with viruses and by key sentinel cells of
the innate immune system: macrophages and dendritic cells
(DCs). Importantly, macrophages and DCs do not have to be
infected by viruses in order to produce IFNs. Instead, they
constantly sample material from the outside, including virus14 vol. 61 j S14–S25
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containing remnants of apoptotic cells and intact viral particles.
Degradation processes in the endosomes then expose viral
nucleic acids to recognition by TLRs. Type II IFN (IFN-c) is pro-
duced by NK and natural killer T cells as part of the innate
immune response, and by antigen-speciﬁc T cells (both CD4+
Th1 and CD8+ cytotoxic T lymphocytes).
Virus infections are sensed by the toll-like receptor (TLR)
dependent pathway [7,8] and the cytosolic pathway, triggered
by binding of viral RNA to the RNA helicases retinoic acid induc-
ible gene-1 (RIG-1) and melanoma differentiation antigen 5
(Mda5) [9,10]. Both pathways converge on the activation of the
key transcription factors NF-jB and the interferon regulatory
factor (IRF) 3 and 7. Activated IRF3 and NF-jB bind to response
elements in the promoters of type I and III IFN genes.
All types of IFNs induce an antiviral state by the transcrip-
tional activation of hundreds of genes. The speciﬁc set of genes
differs between IFNs and target cell type. In general, IFN-as and
IFN-ks induce a largely overlapping set of genes in cells that
express receptors for both IFN-a and IFN-k [11], whereas the
IFN-c-induced gene set is more distinct [12,13]. The number of
genes regulated by IFNs also differs between cells. For instance,
pegylated IFN-a signiﬁcantly induces 200 to 300 genes in the
liver, but nearly 2000 genes in peripheral blood mononuclear
cells (PBMCs) [14].
Type I and II IFNs are essential for the defence against virus.
Knockout mice that lack the receptors for IFN-a or IFN-c, or com-
ponents of the IFN signal transduction pathway succumb to
otherwise harmless viruses [15,16], and infants with genetic
defects of the IFN system die from viral infections despite best
medical care [17]. Type III IFNs have a more restricted role, most
likely in the viral defence at epithelial surfaces in the respiratory
and gastro-intestinal tract [18,19].Interferon signal transduction
IFN-as and IFN-b bind to the ubiquitously expressed IFN-a
receptor. IFN-ks bind a different receptor, consisting of the
ubiquitously expressed IL-10R2 chain (shared with the IL-10
receptor) and a unique IFN-k receptor 1 chain whose expression
is mainly restricted to epithelial cells [20,21]. Off note, IFN-k
receptor 1 expression is very low in control liver biopsy sam-
ples, but signiﬁcantly increased in the setting of chronic viral
infections [22]. IFN-c binds to the widely expressed IFN-c
receptor. IFN receptors connect to the Jak-STAT pathway to
transmit signals from the cell surface to the nucleus [23,24].
All IFNs activate STAT1 to form homodimers that translocate
into the nucleus and bind to gamma-activated sequence (GAS)
elements in IFN-stimulated genes (ISGs). Type I and III IFNs
additionally induce the heterotrimeric transcription factor IFN
stimulated gene factor 3 (ISGF3) that consists of STAT1, STAT2,
and IRF9 and binds to IFN-stimulated response elements (ISRE)
[23,25,26] (Fig. 1). Signalling through the Jak-STAT pathway is
regulated by inhibitors such as SOCS, USP18, PIAS, and TcPTP.
Suppressor of cytokine signalling (SOCS) proteins are rapidly
induced by activated STATs and provide an early negative feed-
back loop [27–29]. Ubiquitin-speciﬁc peptidase 18 (USP18, also
designated UBP43) is another important negative regulator in
type I IFN signalling [30]. USP18 is a key mediator of the refrac-
toriness of liver cells to continuous stimulation with IFN-a [31].
USP18 is not induced by IFN-c, and does not inhibit IFN-c or
IFN-k signalling [32].Journal of Hepatology 201Host-virus interactions in acute hepatitis C
Key Points 1
• Hepatitis C virus (HCV) has a very high replicative 
capacity. Within days after infection, viral titres of 
>106 IU/ml can be measured in the serum
• The innate immune system reacts to HCV infections 
with the induction of interferon (IFN)-stimulated genes 
in the liver. This initial type I and/or type III IFN driven 
response controls viral replication to some extent, but 
can not eliminate HCV completely
• 4-8 weeks after infection, HCV specific T cells are 
recruited to the liver. HCV replication is inhibited by non-
cytolytic (IFN-γ mediated) and cytolytic mechanisms. 
In about 30% of patients, the immune reaction during 
acute hepatitis C is strong enough to eliminate HCV 
infection. 
• In the acute phase of the infection, HCV is highly 
vulnerable to therapy with recombinant IFN-α. Over 
90% of patients can be cured with IFN-α monotherapyInnate immune responses in early acute HCV infection
Prospective studies with health-care workers with AHC after
accidental needlestick injury and with experimentally infected
chimpanzees revealed an enormous replicative capacity of HCV
[33–37]. Already within days after infection, high viral titres have
been measured in the serum and the liver of chimpanzees. After a
very rapid increase in the ﬁrst days (to weeks) after an infection,
HCV viral loads remain stable for several weeks, until the emer-
gence of the cellular immune response in the liver [34–36,38].
ISGs are strongly induced during this entire period, but this
innate immune response is obviously not capable of clearing
HCV infections. As discussed below, several potential mecha-
nisms of viral interference with the IFN system have been
explored, and there is mounting evidence that HCV inhibits the
expression or the function of antiviral effector proteins in
infected cells. The co-existence of high viral loads and high ISG
expression has been interpreted as a proof that the innate IFN
response is completely ineffective against HCV. However, the
short duration of the exponential increase of viral loads and the
following permanent restriction of the viral load during the early
phase of AHC could reﬂect an important role of the innate
immune system in the containment of HCV.
For the following discussion, the acute phase of HCV infection
will be sub-divided in an early acute phase prior to the activation
and recruitment of HCV speciﬁc T cells in the liver, and a late
acute phase, characterized by the adaptive immune response
(Fig. 2). The host reaction in the liver during the early acute phase
of HCV infections has been studied in experimentally infected
chimpanzees [34–36,38] where a strong host-response to HCV
has been detected already days after infection. Transcriptome
analysis revealed induction of type I IFN-stimulated genes
[34,35]. The extent and duration of the ISG induction showed a
positive correlation with viral load [35]. This suggests that the
most important regulator of ISG induction in the early acute
phase is the amount of HCV derived PAMP molecules that
stimulate TLR-dependent and/or RIG-1/Mda5-dependent sensory4 vol. 61 j S14–S25 S15
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Fig. 1. IFN signalling through the Jak-STAT pathway. Type I (IFN-as and IFN-b)
and type III (IFN-ks) IFNs bind to distinct receptors, but activate the same
downstream signalling events, and induce almost identical sets of genes mainly
through the activation of IFN-stimulated gene factor 3 (ISGF3) and STAT1
homodimers. IFN-c (the only type II IFN) activates STAT1, but not ISGF3, and
induces a partially overlapping but distinct set of genes.
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Fig. 2. Natural course of HCV infection. Within days after infection, viral load
rapidly increases to a plateau of 105–107 IU/ml (red line) (IUs approximately
correspond to genome equivalents). In this early phase of acute infection (the ﬁrst
4–8 weeks), an innate immune response driven by type I or type III IFNs (green
line) might restrict viral replication. With the recruitment of HCV speciﬁc T cells
in the late phase of AHC, the gene expression proﬁle in the liver switches to an
IFN-c pattern (yellow line). At the same time, alanine aminotransferase levels
increase (blue line) and some patients get icteric. In late AHC, viral replication is
strongly inhibited, and in about 30% of patients, HCV is completely eliminated
(dashed red line) and alanine transaminase levels return to normal (dashed blue
line). In 70%, HCV persists (solid red line), and alanine transaminase remains
elevated (solid blue line). In the chronic phase of HCV infection, cellular inﬁltrates
persist at a lower level, but IFN-c driven ISG expression disappears. However, in
about half of the patients, type I or type III IFN-stimulated genes are again
strongly induced (green line). The other patients have little to no activation of
ISGs in the liver (light green line). The light blue line shows the upper limit of
normal for alanine transaminase.
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Journal of Hepatology Update: Hepatitis Cpathways. The cellular source and the speciﬁc type of IFN(s),
responsible for ISG induction in this phase of HCV infections,
remain to be clariﬁed. Several recent papers report IFN-k
induction in primary human hepatocytes (PHH) infected with
HCV [39–41]. However, others have proposed that plasmacytoid
dendritic cells, stimulated by cell-cell contact with infected
hepatocytes, are the main producers of IFNs [42]. The clariﬁcation
of the cellular source of IFN in the early acute phase of HCV will
require in situ detection of IFN mRNA in liver biopsies of
experimentally infected chimpanzees.
Technical progress is also required to identify the type(s) of
IFN, responsible for the induction of ISGs. Earlier studies with
chimpanzees failed to detect induction of IFNs in early AHC
[34,35]. More recent studies detected upregulation of mRNA of
type III (but not type I) IFNs in liver biopsies [40,41], and an
increase of type III IFN protein, primarily IFN-k1 (IL29), in the
serum of chimpanzees [41]. IFN-k1 serum concentrations in 6
experimentally infected chimpanzees were in the range of
200 pg/ml during the ﬁrst weeks of infection. In this early phase
of AHC, all animals had a signiﬁcant upregulation of ISGs in the
liver. However, IFN-k1 serum concentrations in the same rangeS16 Journal of Hepatology 201have been measured in healthy (not HCV infected) humans with
presumably uninduced ISGs in the liver [43]. It is also not clear
how well human hepatocytes respond to type III IFNs. In one
report, IFN-k induced ISG expression in PHHs to a similar extent
as IFN-a [44]. Different results were published in another report,
where compared to IFN-a, IFN-ks were very weak activators of
STAT1 phosphorylation in PHHs, because the speciﬁc chain of
the IFN-kR, IFN-kR1, was found to be expressed at very low levels
in uninfected, unstimulated hepatocytes [22]. However, IFN-kR1
could be rapidly induced by IFN-a [22]. The rapid induction of
ISGs in early AHC might well be the results of a combined effect
of type I and III IFNs.
Role of NK cells in the early phase of HCV infection
Natural killer (NK) cells are large granular lymphocytes that
account for the majority of innate immune cells in the human
liver [45,46]. Indeed, they are signiﬁcantly increased in the liver
compared to the peripheral blood although this becomes
especially evident in chronic HCV infection. NK cells play an
important role in the control of viral infections. They have direct
antiviral as well as regulatory effects [46,47]. The direct antiviral
effects are mediated by direct cytolytic (e.g., TRAIL or perforin-
mediated) or non-cytolytic (e.g., IFN-c mediated) effector
functions. Several lines of evidence support a relevant role of
NK cells in acute HCV infection. For example, genetic studies have
demonstrated that genes encoding the inhibitory NK cell receptor
KIR2DL3 and its human leukocyte antigen C group 1 (HLA-C1)
ligand directly inﬂuence resolution of HCV infection in patients
homozygous for these genes [48]. Furthermore, KIR2DL3+-
NKG2A NK cells have been suggested to control early HCV infec-
tion prior to seroconversion and may thus result in an apparent
state of ‘‘natural resistance’’ to HCV in persons who inject drugs4 vol. 61 j S14–S25
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[49]. A possible role of NK cells in HCV immunobiology is further
supported by the ﬁnding that they are activated in acutely
infected subjects, as determined by an increased expression of
the activating receptor NKG2D that is accompanied by an
increased production of IFN-c and cytotoxicity [50]. NK cell
responses are also linked with T cell responses, e.g., increased
degranulation of natural killer cells during acute HCV has been
shown to correlate with the magnitude of virus-speciﬁc T cell
responses [51,52]. Also, an activated multifunctional NK cell
response, i.e., cytotoxicity and IFN-c production, has been
reported early after HCV exposure in healthcare workers who
do not develop acute infection, suggesting an important contribu-
tion to the prevention of high level viremia [53,54].
Adaptive immune responses during acute HCV infection
In contrast to the innate immune responses that are induced
within hours to days after infection, there is a striking and so
far not understood delay of approximately 6–8 weeks before
adaptive immune responses become detectable
[35,38,46,55,56]. Different components of the adaptive immune
system are involved in viral clearance, including humoral anti-
body and T cells responses (Fig. 3A) [57]. Indeed, most acutely
HCV-infected individuals produce antibodies against epitopes
within the structural as well as non-structural proteins. Most of
them, however, have no relevant antiviral activity, and only a
small fraction of antibodies is able to inhibit virus binding, entry,
or uncoating. These antibodies are called ‘neutralizing antibodies’
[58]. Results obtained with a well-characterized and homogenous
group of young women infected by an HCV-contaminated anti-D
immunoglobulin preparation, containing the same virus inocu-
lum (strain AD78), suggest the development of neutralizing anti-
bodies in the early phase of infection in the majority of patients
with resolving HCV infection [59]. In contrast, patients with a
chronic course of infection showed a delayed induction of
neutralizing antibodies [59]. Although this study links an early
neutralizing antibody response with HCV clearance, it remains
unclear whether the neutralizing antibody response really medi-
ates viral clearance. Indeed, it is noteworthy that virus control
and clearance has also been observed in the absence of neutraliz-
ing antibodies and even in hypoglobulinaemic individuals.
There is general consensus, however, that HCV elimination is
associated with strong and sustained CD4+ and CD8+ T cell
responses that target multiple epitopes within the different
HCV proteins [33,38,60–64] and that remain detectable long after
resolution of infection [64]. Several lines of evidence support the
important role of both T cell subsets in controlling HCV infection:
a clear temporal association between the onset of peripheral and
intrahepatic virus-speciﬁc T cell responses and HCV clearance
[33,38,60–64]; a strong association between certain class I (e.g.,
HLA-B27) and class II (e.g., DRB1⁄1101) alleles and spontaneous
elimination of the virus [65]; and ﬁnally, the pronounced impact
of CD4+ and CD8+ T cell depletion on the course of HCV infection
in vivo [66,67]. Indeed, antibody-mediated depletion of CD8+ T
cells prior experimental infection of previously protected chim-
panzees led to HCV persistence until CD8+ T cell response recov-
ered and an HCV-speciﬁc CD8+ T cell response emerged [66].
Depletion of CD4+ cells in previously protected chimpanzees
led to HCV persistence and the emergence of CD8+ escape variant
[67]. Collectively, these ﬁndings indicate that CD4+ T cells are
central regulators, while virus-speciﬁc CD8+ T cells primarilyJournal of Hepatology 201function as the key effectors. The important role of CD4+ T cell
responses has been recently further supported by a study
showing an association between viral clearance and the strong
expansion of CD161+CCR6+CD26+CD4+ T cell responses that pro-
duce IL-17 and IL-21 [68]. Insights into virus-speciﬁc CD8+ T cell
effector functions were forthcoming from in vitro studies. Indeed,
by using a subgenomic replicon-containing cell line that was sta-
bly transduced with the common MHC class I allele HLA-A2 gene
it was shown that HCV-speciﬁc CD8+ T cells exert strong antiviral
effects primarily by IFN-c and only to a lower extent by cytolytic
effector functions [69]. Of note, the possible role of IFN-c during
acute infection has also been supported in transcriptome analy-
ses of liver biopsies of patients and chimpanzees with acute
HCV infection that revealed a strong induction of IFN-c
stimulated genes [13,38]. It is currently unclear why this IFN-c
dominated response succeeds in eliminating the virus in a
considerable proportion of patients, whereas the activation of
the type I or III IFN system in the early phase of AHC invariably
fail. The number of ISGs and the expression level of ISGs seem
not to be signiﬁcantly different in the early vs. the late phase of
AHC. Is there an important qualitative difference in ISG induc-
tion? CD8+ T cell derived IFN-c could stimulate the induction
of a speciﬁc subset of genes that are crucial for HCV elimination.
It is also conceivable that IFNs alone are not sufﬁcient and that
the cellular immune response provides additional antiviral
effector systems. However, such explanations are contested by
the over 90% success rate of therapies with recombinant IFN-a
in AHC patients. Obviously, type I IFNs can induce all the
necessary antiviral effectors in HCV infected cells. Clearly, the
reasons for the failure of the innate immune system in early
AHC remain unknown.Host-virus interactions in chronic hepatitis C
Interferon-stimulated gene expression in chronic hepatitis C
Key Points 2
• In chronic hepatitis C (CHC), HCV escapes both innate 
and adaptive immunity by yet unknown mechanisms
• In a substantial proportion of patients, HCV infection 
induces an IFN mediated innate immune response 
in the liver. The type of IFN (α, β, λ) responsible 
for continuous stimulation of IFN-stimulated gene 
expression and the cells that produce the relevant IFNs 
have not yet been identified
• Induction of the endogenous IFN system in the liver is 
not only ineffective in clearing the viral infection, but 
also prevents response to therapies with pegylated 
IFN-α and ribavirin
In humans who develop chronic infections, ISG induction
varies considerable between individuals. In about half of patients
of Caucasian ethnicity, hundreds of type I or III ISGs are
constantly expressed at high levels in the liver, whereas the other
half has no detectable induction of the innate immune system4 vol. 61 j S14–S25 S17
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Fig. 3. Success and failure of virus-speciﬁc CD8+ T cell responses. (A) CD8+ T cells can inhibit viral replication by cytolytic (perforin) and non-cytolytic (IFN-c) effector
mechanisms. Help by CD4+ T cells is required. Neutralizing antibodies may block the virus and thus infection of further hepatocytes. (B) Several different mechanisms
contribute to the failure of adaptive immune responses in HCV infection, such as viral escape, T cell exhaustion, as indicated by the expression of inhibitory receptors, lack of
CD4+ T cell help or the action of regulatory T cells.
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Journal of Hepatology Update: Hepatitis C[70]. Apart from a strong association of allelic variants near the
IFN-k4 gene with ISG induction [71–75], little is known about
the factors that determine the activation level of the IFN system.
Inter-individual variability of MAVS cleavage by NS3/4A is prob-
ably involved. In liver biopsies of patients with CHC, the degree of
MAVS cleavage inversely correlates with ISG expression, but the
correlation is rather weak [76].
The induction of the endogenous IFN system in the liver
apparently has little antiviral efﬁcacy. HCV persists for decades
despite the expression of hundreds of ISGs [14,77,78].
Furthermore, there is no signiﬁcant correlation between serumS18 Journal of Hepatology 201or intrahepatic viral loads with ISG expression levels [70,76].
The mechanisms of viral interference with the hepatic IFN system
remain to be elucidated. There are numerous reports of viral
interference with Jak-STAT signalling and ISG induction in cell
culture systems. However, this has not been conﬁrmed in human
liver biopsies. On the contrary, using a recently developed in situ
hybridization method that allows the detection of HCV RNA in
human liver biopsies, HCV RNA and mRNA of ISGs were found
to be co-expressed in hepatocytes [70]. Alternatively, HCV could
inhibit cap-dependent protein translation at the ribosomes
[14,77,78]. In cell culture experiments, HCV infection triggers4 vol. 61 j S14–S25
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phosphorylation and activation of the RNA-dependent protein
kinase PKR, which phosphorylates eukaryotic translation initia-
tion factor eIF2a [79]. Because phosphorylated eIF2a inhibits
cap-dependent translation, no proteins are produced from ISG
mRNAs. Of note, HCV protein production is not impaired, because
HCV RNA translation occurs through an internal ribosomal entry
site (IRES) dependent mechanism that is not impaired by
phosphorylated eIF2a [79]. If HCV indeed inhibits ISG protein
translation in hepatocytes of infected patients remains to be
clariﬁed. A third possible level of viral interference with the IFN
system could also be downstream of ISG protein production.
HCV replication could occur in subcellular compartments that
are not accessible to antiviral proteins, induced by IFNs, or HCV
proteins could bind to and antagonize antiviral ISG proteins
[13]. Progress in this controversial ﬁeld will only come with
advanced imaging studies that allow detecting HCV RNA and
proteins and ISG mRNAs and proteins on a single cell level in liver
biopsies from patients with CHC.
Non-response to PegIFN-a in CHC patients with an activated
endogenous IFN system in the liver
It is now ﬁrmly established that patients with an activated
endogenous IFN system are poor responders to IFN-a based ther-
apies [14,77,78,80]. Analysis of paired liver biopsies obtained
before treatment and 4 h after the ﬁrst injection of PegIFN-a2
revealed that patients with an activated endogenous IFN system
had hundreds of ISGs expressed at high levels already before
treatment, and that PegIFN-a2 did not further increase the
expression of these genes, i.e., was completely ineffective in the
liver [14]. In such biopsies, staining for the phosphorylated
(activated) form of STAT1 revealed a faint staining in nuclei of
hepatocytes in pre-treatment biopsies, and no further increase
of phospho-STAT1 signals 4 h after PegIFN-a injections [14]. In
contrast, no phospho-STAT1 signals were detected in pre-treat-
ment biopsies of ‘‘responder’’ patients without constitutive
induction of ISGs, but PegIFN-a injections induced a very promi-
nent and strong activation and nuclear translocation within 4 h
[14]. The reason for the apparent refractoriness of IFN-a induced
Jak-STAT signalling is not entirely clear, but there is evidence that
USP18 is an important factor. USP18 was strongly expressed in a
large number of hepatocytes in liver biopsies from patients with
CHC and a pre-activated endogenous IFN system [13]. Moreover,
there is convincing genetic evidence from knockout mice experi-
ments that USP18 is responsible for the long-term refractoriness
of IFN-a signalling in the liver [31]. These observations generate
an apparent paradox: Since USP18 is not constitutively expressed
in cells, but is only expressed after IFN stimulation, how can its
expression level be maintained at high levels despite complete
refractoriness of IFN-a signalling? Or in more general terms:
How can an IFN-a induced negative regulator of IFN-a signalling
be persistently induced?
The driving force of ISG expression in CHC
The subtype(s) of IFN that drive the permanent expression of ISGs
in CHC have not been identiﬁed, and little is known about the
cellular source of IFN(s), too. mRNA expression of IFN-as, IFN-b,
IFN-c has not been consistently detected in liver biopsies from
patients with CHC, even in samples with very high expression
of ISG mRNAs. IFN-c can be further excluded as driver of ISGJournal of Hepatology 201expression in CHC because the set of ISGs induced in CHC con-
tains typical type I IFN-stimulated genes, but not type II induced
ISGs [13,14,81]. IFN-as can be tentatively excluded because IFN-a
signalling is subject to strong negative feedback inhibition, spe-
ciﬁcally by USP18, that would prevent long-lasting activation of
ISGs [13,30,31]. One could only argue that the refractory state,
caused by USP18, is leaky and allows low-level STAT1 activation
below the detection limit of phospho-STAT1 Western blots or
immunostaining techniques. However, there are more appealing
alternative explanations. Interestingly, USP18 does not inhibit
IFN-k signalling [32]. Contrary to all other IFN subtypes, IFN-k1,
-k2, -k3, and the recently discovered IFN-k4 mRNA can be
detected in liver biopsies [71,82]. Admittedly, it is presently
unknown if the low amount of mRNA detected produces enough
bio-active protein to explain the strong induction of ISGs in CHC.
No IFN proteins have been detected so far in liver biopsies of
patients with CHC. However, considering the fact that IFN-k sig-
nalling is not refractory, IFN-ks remain strong candidates for
being the drivers of constitutive ISG induction in CHC patients
with an activated endogenous IFN system.
IFNk3/4 genotype and innate immune responses to hepatitis C virus
Key Points 3
• Genetic variants of the IFN-λ3 and IFN-λ4 locus are 
strongly associated with spontaneous clearance of HCV 
and with response to therapy with pegylated IFN-α and 
ribavirin
• The ancestral IFN-λ4 ∆G allele (associated with poor 
response to therapy) is positively associated with 
IFN-stimulated gene expression in CHC
• The molecular mechanisms that link genetic variants 
near the IFN-λ4 gene with constitutive activation of the 
endogenous IFN system in the liver are not entirely 
known, but might involve an ongoing stimulation of 
the Jak-STAT pathway by INF-λ4 through the IFN-λ 
receptors on hepatocytes
The discovery of a strong association of genetic variants near
the IFN-k3 gene with response to PegIFN-a2/ribavirin combina-
tion treatment of CHC and with spontaneous clearance of HCV
has been a major step towards a better understanding of the
genetic factors that control natural history, host-virus interac-
tions and IFN responsiveness in individual patients [83–87]. More
recently, an additional variant in this gene region has been
described, and contrary to the other single nucleotide polymor-
phisms (SNPs) that have no obvious functional consequences in
terms of gene expression or amino acid changes, the newly dis-
covery TT/DG SNP directly controls the expression of IFN-k4
(Fig. 4) [74]. The ancestral allele with the sequence gccGctg at
position rs368234815 can give rise to a transcript with an open
reading frame of 179 AA, coding for IFN-k4. The insertion of a T
and the change of the G to a T (resulting in the sequence gccTTctg
at rs368234815) disrupt the open reading frame [74]. The TT
allele is more frequent in Caucasians, but not in Africans.
Paradoxically, the IFN-k4 producing allele is associated with
reduced spontaneous clearance rates of HCV infections and also4 vol. 61 j S14–S25 S19
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Fig. 4. IFN-k3/4 gene locus on human chromosome 19. The originally described SNPs strongly associated with spontaneous and treatment induced HCV clearance are
located in the ﬂanking regions of the IFN-k3 (IL28B) gene (highlighted in red) [83–87]. The more recently described SNP rs368234815 (highlighted in blue) is linked to two
alleles, the DG and the TT alleles. The DG allele codes for IFN-k4 (light blue). The insertion of a T in the TT allele introduces a frame shift and premature stop codon. The TT
allele cannot code for a functional IFN-k4 transcript. Nucleotide numbers on chromosome 19 are indicated for the SNPs and for the start of the IFN-k3 and IFN-k2 genes.
B
a
si
c
Journal of Hepatology Update: Hepatitis Ca dramatically reduced rate of sustained virological response to
treatment with pegylated IFN-a and ribavirin [74,75,88]. The
molecular link between genotype and phenotype remains to be
elucidated. Importantly, the IFN-k4 producing DG allele is
associated with high ISG expression in pretreatment biopsies
[82,89,90], and given the strong association of hepatic ISG expres-
sion with non-response to treatment with pegylated IFN-a and
ribavirin, it is reasonable to speculate that IFN-k4 induced ISG
expression could be the molecular link between genotype and
phenotype [83,84,86,87,91].
NK cell responses in chronic infection
In chronic HCV infection, NK cells are activated but may display
alterations in phenotype and function [92]. For example, NK cells
from chronically HCV infected patients express higher levels of
several activating receptors, such as NKp30 and NKp46 [46,93].
Chronic exposure of NK cells to endogenous INF-a can result in
increased STAT expression, and preferentially STAT1 over STAT4
phosphorylation [94,95]. Interestingly, however, similar NK cell
phenotypic and functional alterations can equally be observed
in chronic HBV and HDV infection, suggesting that these altera-
tions may not be mediated by the virus but rather by disease-spe-
ciﬁc factors [96]. On the other hand, speciﬁc downregulation of,
e.g., NKp30 in HCV infected cells and subsequent inhibition of
NK cell function argues for a virus-speciﬁc effect [97]. Whatever
the explanation, several groups have shown that NK cells,
obtained from chronically infected patients, are impaired in anti-
viral effector function [98,99]. Interestingly, NK cells seem to be
impaired especially in their ability to secrete IFN-c, as has been
reported by several but not all groups. However, cytokine-stimu-
lated NK cell lines and primary NK cells, isolated from healthy
donors, can lyse HCV-replicating cells, particularly at high effec-
tor-to-target ratios [100] and also secrete IFN-c that mediates
the inhibition of HCV replication [101]. Importantly, IFN-c pro-
duction by human natural killer cells in response to HCV-infected
hepatoma cells is dependent on accessory cells, such as mono-
cytes and plasmacytoid dendritic cells [102]. HCV may directly
interfere with the action of NK cells. For example, a recent report
suggests that NS5A-containing apoptotic bodies can trigger
monocytes to produce increased amounts of IL-10 and decreased
levels of IL-12 that leads to a signiﬁcant downregulation of
NKG2D on NK cells via TGF-b [103]. Another study has suggestedS20 Journal of Hepatology 201that cell-to-cell contact with HCV-infected cells reduces func-
tional capacity of natural killer cells [104] although NK cell func-
tion remains intact after exposure to infectious virus [105]. HCV
mediated inhibition of NK cell mediated augmentation of com-
plement synthesis has also recently been reported [106].
Of note, similar to the predictive value of high pretreatment
ISG levels, NK cell responses can be used as an indicator of a
patients’ IFN responsiveness. Indeed, higher pretreatment levels
of inhibitory receptors, such as NKG2A or activating receptors,
such as NKp46 on NK cells, predict treatment failure [107–109].
Also, dynamic changes of NK cells are observed during therapy
with an association between higher NK perforin content, lower
CD16 expression, and higher natural and antibody-dependent
NK cell cytotoxicity with a virological response [110]. Patients
with a rapid ﬁrst phase HCV RNA decline after initiation of IFN-
based therapy show a maximal phospho-STAT1 induction
in vivo and are refractory to further IFN-a stimulation in vitro.
In contrast, patients with a slow ﬁrst phase HCV RNA control
show lower phospho-STAT levels in their NK cells and the IFN-
a responsiveness is retained. Also, treatment responders show
greater levels of NK cell degranulation than non-responders,
speciﬁcally in the ﬁrst 12 weeks of therapy [94,111].
Adaptive immune responses in chronic hepatitis C
HCV can persist in the majority of chronically HCV infected
patients despite the presence of HCV speciﬁc neutralizing anti-
bodies and T cell responses. The latter contribute most likely to
the progression of liver disease. Multiple mechanisms for the fail-
ure of the adaptive immune responses have been suggested
(Fig. 3B). For example, evolution of viral quasi-species within
targeted epitopes may lead to escape from neutralizing
antibodies and T cells [112]. Interactions of HCV glycoproteins
with high-density lipoprotein (HDL) and the scavenger receptor
B1 (SCARB1) may protect from neutralizing antibodies (100),
and speciﬁc glycans on E2 may modulate cell entry and confer
protection from neutralizing antibodies [113,114]. Interestingly,
it has also been suggested that HCV may evade neutralization
by direct cell to cell transfer of the virus [115,116].
HCV speciﬁc T cell failure is primarily caused by T cell exhaus-
tion and the emergence of viral escape mutations. However,
results obtained from the early phase of acute HCV infection in
chimpanzees [38] and in health care workers infected via4 vol. 61 j S14–S25
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needlestick exposure [33] also support the hypothesis that at
least in some patients virus-speciﬁc T cells are not or only weakly
primed during acute HCV infection. Impaired priming of
HCV-speciﬁc CD8+ T cells might be mediated by low numbers
or functional impairments of antigen-presenting cells such as
macrophages or dendritic cells [47].
In most chronically HCV infected patients, however, virus-
speciﬁc T cells are present and even enriched in the liver [65].
Viral escape in HCV infection has ﬁrst been reported in
chronically infected patients [117] and experimentally infected
chimpanzees [118,119], and subsequently in acutely infected
humans [120,121]. Of note, the emergence of viral escape muta-
tions seems to be associated with the development of chronic
infection, and the absence of escape mutations is associated with
viral clearance [120]. Viral escape, however, is not universal.
Indeed, the occurrence of viral escape may be limited by insufﬁ-
cient CD4+ T cell help, by a limited TCR diversity, by functional
alterations of CD8+ T cells, or by viral ﬁtness cost, e.g., the inabil-
ity of the virus to tolerate mutations in certain viral regions [65].
Indeed, ﬁtness cost might not only explain the occurrence of
reversion after removal of T cell pressure or the absence of viral
escape in speciﬁc CD8+ T cell epitopes [122,123], but may also
directly contribute to the protective effect of speciﬁc CD8+ T cell
responses [122]. Importantly, this has been suggested to be the
case for the protective HLA-B27 and HLA-A3 alleles [124,125]
where epitopes are targeted that do not easily allow viral escape
mutations because of high costs to viral replicative ﬁtness. It is
important to note that viral escape is not limited to CD8+ T cell
epitopes. Indeed, escape mutations can also occur in MHC
class II-restricted epitopes although they are rarely found in
chronically infected patients and chimpanzees [126].
A hallmark of chronic HCV infection is the presence of func-
tionally impaired virus-speciﬁc CD8+ T cells that are character-
ized by their inability to secrete antiviral cytokines, such as
IFN-c, or to proliferate [57,127]. This state of T cell exhaustion
is characterized by an upregulation of inhibitory receptors, such
as PD-1 [128–131] and a low expression of CD127 [128,131].
Intrahepatic HCV-speciﬁc CD8+ T cells with a high PD-1 expres-
sion are prone to apoptosis [132]. Importantly, the impaired pro-
liferative response of CD127-PD-1+ HCV-speciﬁc CD8+ T cells to
antigenic stimulation can be increased by blocking antibodies
targeting PD-1 [128,129,131]. However, the dysfunction of
CD127- cells is not solely caused by inhibitory signals via PD-1,
since PD-1 blockade alone was unable to restore the function of
strongly inhibited HCV-speciﬁc CD8+ T cells in the liver, and
targeting of additional inhibitory receptors, e.g., CTLA-4 or
TIM-3 may be required for restoration of T cell function
[133,134]. Noteworthy, the expression of TIM-3 may speciﬁcally
identify exhausted HCV speciﬁc CD8+ T cells in the liver [135].
Indeed, the liver environment itself has been recently shown to
affect the expression pattern of inhibitory receptors on virus-
speciﬁc CD8+ T cells [135]. A recent study has also suggested a
role for 2B4 in HCV-speciﬁc CD8+ T cell dysfunction [136]. Thus,
it appears that T cell exhaustion is not mediated by a single but
rather by the co-expression of several different inhibitory recep-
tors. Indeed, CD127low HCV-speciﬁc CD8+ T cells were shown to
co-express the inhibitory receptors 2B4, KLRG1, and CD160 in
addition to PD-1 in chronic HCV infection [137]. These observa-
tions may also explain the limited clinical efﬁcacy of PD-1 treat-
ment in chronically infected humans and chimpanzees [138,139].Journal of Hepatology 201It is also important to note that PD-1 expression during acute
HCV infection does not predict the outcome of infection, suggest-
ing that PD-1 may rather be a marker of activation than exhaus-
tion, at least during acute infection [140,141].
Next to the expression of inhibitory receptors, the lack of
CD4+ T cell help or the action of regulatory T cells or cytokines
may also contribute to virus-speciﬁc CD8+ T cell exhaustion.
Indeed, weak and dysfunctional HCV-speciﬁc CD4+ T cell
responses have been reported in chronic infection [142]. Also, a
higher frequency of suppressive CD4+CD25+ T cells has been
found in in chronically HCV-infected patients [143–145]. HCV
speciﬁcity in vivo might be mediated by the enrichment of
CD4+CD25+ T cells in the liver [146] where they might limit
immunopathology in the chronic phase of HCV infection by
inhibiting virus-speciﬁc CD8+ T cells by direct cell to cell contact
[147]. Another type of regulatory T cells in HCV infection are
virus-speciﬁc regulatory CD8+ T cells that express high levels of
IL-10. These regulatory T cells have been detected in the liver
of HCV-infected individuals and their suppression of virus-spe-
ciﬁc CD8+ effector T cells could be blocked by neutralizing IL-
10 antibodies [148,149].
Collectively, these results suggest that several different mech-
anisms contribute to HCV-speciﬁc T cell dysfunction, however,
the relative contribution of each of these different pathways
needs to be clariﬁed in future studies. The contribution of ongo-
ing antiviral therapy is also not entirely clear. Indeed, in contrast
to early successful treatment with pegylated type I IFN during
acute infection that has been shown to lead to restoration of
virus-speciﬁc CD8+ T cell function, IFN therapy in chronic infec-
tion has not been reported to lead to HCV speciﬁc CD8+ T cell res-
toration [150–153]. Interestingly, however, direct antiviral IFN
free therapies can restore HCV-speciﬁc CD8+ T cell function
[154]. Although this needs to be conﬁrmed in further studies
using different antiviral regiments, these results may indicate
that ongoing replication may directly contribute to HCV-speciﬁc
CD8+ T cell failure.Conclusion and perspectives
In recent years, we have seen a tremendous development of
potent new direct acting antiviral IFN free therapy regiments that
lead to sustained virological response rates of almost up to 100%.
This is amazing, considering that HCV has been identiﬁed only a
quarter of a century ago. Also, in these years, important novel
insights into innate and adaptive immune responses and their
role in determining the outcome of natural infection and treat-
ment response have been made. Indeed, the study of host virus
interactions in HCV infection has not only increased our under-
standing of the pathogenesis of one of the most important liver
diseases worldwide, but has also made important contributions
in basic innate and adaptive immunity of chronic viral infections
in general. For example, we have learned about several general
but also about unique escape strategies, utilized by HCV to avoid
recognition by innate and adaptive immune responses. It is strik-
ing that HCV can persist, despite a rapid, strong and sustained IFN
response. Also, when chronically infected patients with induced
ISGs are treated with PegIFN-a and ribavirin, virological response
is very rare. Thus, the endogenous IFN system does not only fail
to eliminate HCV, it even inhibits response to therapeutically4 vol. 61 j S14–S25 S21
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injected recombinant IFN-a. In another group of patients with
CHC, HCV seems to be largely ignored or tolerated by the immune
system. In these patients, the IFN system can be activated thera-
peutically by treatment with PegIFN-a and ribavirin with a high
chance of a sustained virological response. The underlying
molecular mechanisms are not known. It is interesting to note,
however, that ISG induction is positively correlated with viral
load and that inhibition of viral replication, e.g., by anti-miR122
resulted in a simultaneous decline of ISG induction in the liver
[155]. Adaptive immune responses fail, due to the emergence of
viral escape mutations, and the development of functional alter-
ations. Although we have learned a great deal about the possible
mechanisms contributing to the failure of innate and adaptive
immune responses, there are still several important questions
that yet have to be solved. For example, very little is currently
known about the interaction between innate and adaptive
immune responses. This important question is difﬁcult to address
in the absence of infectious small animal models. Recent studies
in the LCMV mouse model, however, have suggested that early
IFN induction may interfere with the induction of virus-speciﬁc
T cell responses [156]. Thus, it is tempting to speculate that early
IFN induction may also be associated with the late priming of T
cells or may even contribute to viral persistence by inhibiting
HCV replication to a degree that it is not recognized by the
adaptive immune response.
In addition, a thorough understanding of host-virus interac-
tions is a prerequisite for the rational design of a vaccine. Further-
more, the strong association of the IL28B (IFN-k4) genotype with
spontaneous clearance of HCV and response to treatments with
(and without) IFNs is a landmark discovery in HCV (and GWAS)
research. The elucidation of the molecular mechanisms that link
the IFN-k4 genotype with basic host reactions, such as spontane-
ous virus control and with the response to antiviral therapies
remains an important challenge in the ﬁeld. Taken together, there
is clearly no reason for a declining interest of the hepatology
research community in host-virus interactions in HCV infections
as several important biological and clinical relevant questions
still need to be addressed. This is of utmost importance not only
for a better understanding of HCV but also of liver disease and
viral hepatitis immunobiology in general.Conﬂict of interest
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